Prenetics names Caroline Levy independent director as IM8 parent readies Q2 results

Prenetics Global Limited, which the company describes as a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham¹, announced on August 17, 2026 that it had appointed Caroline Levy to its Board of Directors as an independent director. According to the company's Form 6-K, the appointment was effective August 17, 2026¹.

Levy will join the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. The filing states she is replacing Dr. Darshan Shah on each of those committees¹, though Shah will continue to serve on the Board of Directors as an independent director¹.

Levy's background includes work at three firms covering the consumer sector. She previously led U.S. consumer research at UBS, where over a decade she also held the role of Chief Operating Officer of Research and chaired the firm's Investment Review Committee, according to the release. She went on to spend eight years as a managing director and senior analyst at CLSA, and most recently covered beverages at Macquarie, per the filing. The company also said Ms. Levy is a current member of the Board of Directors of Celsius Holdings, Inc. (NASDAQ: CELH), where she has served since 2020¹.

Prenetics said its flagship brand, IM8, is a subsidiary of Prenetics (NASDAQ: PRE)¹. The company also noted that Prenetics will report its second quarter 2026 financial results tomorrow, Tuesday, August 18, 2026, and will host a live earnings webcast at 8:30 a.m. Eastern time on StockTwits¹. CEO Danny Yeung and CFO Brian Rosin are expected to present results alongside Levy and a Scientific Advisory Board member, followed by a question and answer session with research analysts, the filing said.